By 2008, the manufacturer (Palatin Technologies) halted nasal formulation trials and pivoted to a subcutaneous injection route, which showed fewer cardiovascular side effects
However, these endorsements may be based on something other than scientific evidence, leading to the spread of misinformation
"A suitable candidate for Ozempic is someone comfortable with weekly self-injections, has a history of type 2 diabetes, and a body mass index (BMI) of 27 or higher," explains Dr
Ozempic isnt licensed for weight loss in the UK, and liraglutide, while licensed, has been superseded by more effective options
Do not take 2 tablets on the same day to make up for the missed one
They're quite small right now, but I'm not sure what to do about them